604 results on '"Chan, Wah‐Kheong"'
Search Results
2. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
3. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
4. Global burden of metabolic diseases, 1990–2021
5. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021
6. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus
7. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
8. Prevalence and risk factors for impaired renal function among Asian patients with nonalcoholic fatty liver disease
9. Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
10. An international multidisciplinary consensus statement on MAFLD and the risk of CVD
11. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
12. acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study
13. Sequential SAFE Score and Transient Elastography for Detecting Significant Fibrosis in Asian Patients with MASLD
14. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients
15. A systematic review on factors associated with non-alcoholic fatty liver disease (NAFLD) among adolescents
16. A global research priority agenda to advance public health responses to fatty liver disease
17. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
18. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma
19. Nonalcoholic Fatty Liver Disease: A Unique Entity or Part of the Metabolic Syndrome or Both
20. Validation of the Hepamet fibrosis score in a multi-ethnic Asian population
21. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
22. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
23. SAT-438 Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
24. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry
25. A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease
26. LIVERSTAT for risk stratification for patients with metabolic dysfunction‐associated fatty liver disease.
27. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study
28. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study
29. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
30. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
31. Nonalcoholic Fatty Liver Disease: A Global Perspective
32. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
33. Diagnostic accuracy of non‐invasive tests to screen for at‐risk MASH—An individual participant data meta‐analysis.
34. Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity.
35. Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease
36. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
37. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
38. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
39. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
40. Volumetric Liver Fat Fraction Determines Grade of Steatosis More Accurately Than Controlled Attenuation Parameter in Patients With Nonalcoholic Fatty Liver Disease
41. Metabolic fatty liver syndromes: where do we stand in 2024?
42. Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
43. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
44. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
45. Epidemiology of non-alcoholic fatty liver disease in Asia
46. Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance
47. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis
48. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
49. Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—the MAFLD fibrosis score. Authors' reply
50. Prevalence of metabolic syndrome and metabolic dysfunction-associated fatty liver disease in Malaysia 2023: study protocol for a community-based nationwide cross-sectional survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.